A Phase III Clinical Trial Evaluating De-Escalation of

Recruiting

99 years or below

All

147 participants needed

1 Location

Brief description of study

Comparison of endocrine therapy alone (experimental arm) vs breast radiation and endocrine therapy (SOC) in hormone-sensitive, stage 1 breast cancer post lumpectomy. Oncotype Recurrence Score must be less than or equal to 18 in order to participate. The experimental arm will be tested for non-inferiority. HRQOL will be collected with several PRO assessment tools. Subjects will have option to supply blood and left-over tumor tissue for biobank and correlative studies.

Detailed description of study

Added

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 19 Sep 2024. Study ID: 852693

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I Hormone Sensitive HER2-Negative Oncotype Recurrence Score 18 Breast Cancer (DEBRA* DE-escalation of Breast RAdiation)

Brief description of study

Detailed description of study

Eligibility of study

Find a site

Interested in the study